AEON Biopharma, Inc. has shared encouraging results from their recent Phase 2 medical trial of ABP-450.

TScan Therapeutics, Inc.announced today that the U.S. FDA has given approval for its new experimental drug TSC-203-A0201, a TCR-T pinpointing PReferentially expressed Antigen in Melanoma.

SparingVision has shared encouraging early safety data from the Phase I/II clinical trial of its primary gene-agnostic gene therapy, SPVN06, designed to treat retinitis pigmentosa.

This article summarized the latest R&D progress of Methimazole, the Mechanism of Action for Methimazole, and the drug target R&D Trends for Methimazole.

Janssen has filed an additional Biologics License Application with the U.S. Food and Drug Administration, seeking endorsement for RYBREVANT® (amivantamab-vmjw) to be combined with Chemotherapy.

This article summarized the latest R&D progress of Sevelamer Carbonate, the Mechanism of Action for Sevelamer Carbonate, and the drug target R&D trends for Sevelamer Carbonate.

Tourmaline Bio reported that the FDA has conditionally approved the Investigational New Drug (IND) application for TOUR006.

Research on tumor immune evasion and tolerance mediated by exosomes has found that tumor cells can produce a large amount of exosomes.

The inaugural patient has been administered with ATSN-201 under the Phase I/II Clinical Trial, for combatting X-linked Retinoschisis, as announced by Atsena Therapeutics.

This article summarized the latest R&D progress of Argatroban, the Mechanism of Action for Argatroban, and the drug target R&D trends for Argatroban.

The U.S. FDA has sanctioned the use of Bristol Myers Squibb's Reblozyl® (luspatercept-aamt) as an initial treatment option for anemia in adults suffering from low-risk Myelodysplastic Syndromes (MDS) who might need transfusions.

This article summarized the latest R&D progress of Pimobendan, the Mechanism of Action for Pimobendan, and the drug target R&D Development for Pimobendan.